Prevention and treatment of viral infection and viral infection-induced organ failure
US11197912B2 · kind B2 · utility
0Cited by
8References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 25, 2021 |
| Grant date | Dec 14, 2021 |
| Priority date | — |
| Expiry date | Feb 25, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions for and methods of preventing, reversing or treating viral infection-induced organ failure provided. The compositions are also suitable for treating and/or preventing COVID-19 and influenza. The compositions and methods employ MG53, which can be in the form of recombinant human MG53. The MG53 may also be administered as a composition that expresses and releases MG53 after in vivo administration of said composition to a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.